The Comparison of Effects of Applications of Compound 48/80 and Mast Cell Mediator Suspension on Inflammation in Rats: A Methodological Study for Acute Inflammatory Pain

Erkan Kilinc1, Yasar Dagistan2, Ayhan Cetinkaya2, Fatma Tore1

1Department of Physiology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey
2Department of Neurosurgery, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey

Correspondence Author: Erkan Kilinc
E-mail: e_kilinc_27@hotmail.com
Received: 03.01.2018    Accepted: 07.02.2018

ABSTRACT

Objective: Inflammation underlies the pathological basis of most diseases. Substance-P is a key mediator that participates in various inflammatory processes and painful conditions. Mast cells (MCs) have a key role in inflammatory processes via mediators released from their granules. The experimental models for the investigation of pathogenesis and treatment of inflammatory diseases represent merely certain characteristics of inflammatory cases, therefore, more comprehensive models are required. We aimed to compare effects of administrations of the compound-48/80 and mast cell mediator suspension (MCMS) obtained from peritoneal MCs on the inflammation in rats.

Methods: Rats were divided into five groups (n=6): Intraperitoneally, Control group received 0.2 ml saline; C-48/80 group received 2 mg/kg compound-48/80; MCMS group received 0.2 ml MCMS; C+C-48/80 group received 10 mg/kg cromolyn plus compound-48/80; Cr+MCMS group received cromolyn plus MCMS. Potent inflammatory markers, plasma substance-P levels, and number and degranulation of dural MCs were measured. Data were analyzed using one-way ANOVA followed by Dunnett’s post hoc test.

Results: Compound-48/80 increased plasma substance-P levels (p<0.05) and dural MC-degranulation (p<0.001). Likewise, MCMS increased substance-P levels and dural MC-degranulation (p<0.001) as well as number of dural MCs (p<0.01). MC stabilizer cromolyn inhibited increases in the parameters induced by compound-48/80 and MCMS (p<0.01 and p<0.05, respectively).

Conclusion: MCMS administration had greater impact to increase the plasma substance-P levels and number and degranulation of dural MCs than that of the compound-48/80 administration. The results demonstrate the potent inflammatory effect of MCMS treatment over the compound-48/80 administration. Administration of MCMS could be a useful tool to study inflammatory conditions.

Keywords: Inflammatory pain, mast cell degranulation, substance-P, compound-48/80.

1.INTRODUCTION

Inflammation is a complex biological response of tissues to endogen or exogen detrimental stimuli. Acute inflammation is induced by various stimuli including chemical mediators generated by damaged host cells, infections, chemical agents, tissue injuries, and immune reactions. Inflammation is characterized by pain, swelling, and leukocyte infiltration in the site of injury (1). Mast cells (MCs) are tissue resident inflammatory cells participating in immune responses during inflammatory reactions (2). Normally activation of MCs is useful to establish homeostasis of body systems, but their over activation can chronically induce inflammatory responses such as in the case of asthma and arthritis (3). MCs participate in the inflammatory processes by releasing various pronociceptive, vasoactive and pro-inflammatory mediators from their granules through a process called degranulation (4). MC-derived mediators such as serotonin, prostaglandin, histamine, tryptase, tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-1β are able to trigger and enhance inflammatory reactions (5). Increments in the number and degranulation of MCs in their resident environment contribute to hyperalgesia in various rodent models of pain (6,7). It was previously reported that chronic inflammatory processes following pathological stimuli can be restrained by application of mast cell stabilizing agents such as ketotifen and cromolyn (8,9).

Substance P (SP) is a neuropeptide consisting of 11 amino acids and is produced by neurons and cells of the immune system such as MCs, macrophages, and dendritic cells. It exerts its effects by binding to the neurokinin-1 receptor (NK-1R) (10). SP is a crucial mediator of inflammation, and plays a key role in the generation and maintenance of inflammation. It is involved in the pathophysiology of various inflammatory diseases such as rheumatoid arthritis and joint inflammation (11, 12). SP participates in the inflammatory processes by inducing the release of proinflammatory cytokines such as IL-1, IL-2 and TNF-α from various cells (13). Inhibition of substance P activity by using NK-1 receptor antagonists or via gene deletion produces potent anti-inflammatory analgesic effects (14) and reduces edema formation in humans (15). Increased number and enhanced degranulation of MCs, and increased...
SP levels accompanying hyperalgesia have been involved in various pathologies associated with pain (7). Animal models of inflammatory pain are important tools to investigate pain mechanisms and analgesic effects of potential drugs for the treatment of inflammatory diseases. Various inflammatory substances including inflammatory cytokines, formalin, lipopolysaccharide and Freund’s adjuvant have been used to construct animal models of inflammatory pain via application of these substances to cutaneous tissues, joints and muscles (16). Yet, none of these models mimic all the characteristics of inflammatory pains, however, they represent certain points of inflammatory pain conditions. Herein, we have compared effects of intraperitoneal administrations of the basic secretagogue agent compound 48/80 which is used to produce hyperalgesia and inflammation associated with the degranulation of mast cells as well as mast cell mediator suspension obtained from peritoneal MCs on the inflammation in rats.

2.METHODS

2.1.Experimental Animals

Thirty male Wistar rats weighing 170-200 g were used in present study. The rats received a standard pellet diet and water *ad libitum* and were housed in their cages with a 12 hour light/dark cycle at 22 ± 2 °C. All experimental applications were approved by Animal Experiments Local Ethics Committee of Abant Izzet Baysal University (licence number 2017/23).

2.2. Reagents

Compound 48/80, cromolyn sodium salt, toluidine blue, phosphate-buffered saline (PBS) and paraformaldehyde (PAF) were purchased from Sigma-Aldrich, (Schnelldorf, Germany). Substance-P ELISA kit was purchased from ELABscience (Wuhan, P.R. China).

2.3.Experimental groups and treatments

Thirty rats were randomly divided into five groups with six rats in each group. Intraperitoneal administration were performed as follows; rats in control group (n=6) were administered with 0.2 ml normal saline; rats in C-48/80 group (n=6) were administered with mast cell degranulating agent 2 mg/kg compound 48/80 (17); rats in mast cell mediator suspension (MCMS) group (n=6) were administered with 0.2 ml autologous mast cell mediator suspension (1.5×10⁵/ml cells); 30 min prior to the administration of compound 48/80, rats in Cromolyn+C-48/80 group (n=6) were treated with mast cell stabilizer agent with an amount of 10 mg/kg cromolyn sodium (8); 30 min prior to the administration of 0.2 ml autologous mast cell mediator suspension, rats in Cromolyn+MCMS group (n=6) were treated with 10 mg/kg cromolyn sodium.

2.4. Isolation of peritoneal mast cells from rats

Peritoneal mast cells were obtained from rats using peritoneal saline washing method as previously described (18). Rats were anesthetized with ketamine (90 mg/kg, i.p.). Peritoneal lavage was carried out by injecting 10 ml normal saline containing heparin (5 U/ml) into peritoneal cavity. Abdominal massage was gently applied to the rats for 4 min. Then, 6 ml of peritoneal mast cell rich fluid was collected with a 10 ml syringe from the peritoneal cavity. The fluid was then centrifuged at 32 g for 2 min at room temperature. Precipitated peritoneal mast cells were mingled in 1 ml PBS and counted using a thoma chamber. To obtain mast cell mediator suspension, peritoneal mast cells in PBS were treated with compound-48/80 (10 µg/ml) for 15 min at 37 °C (17). Isolation of peritoneal mast cells were carried out to all rats to standardize experimental groups, but only rats in the MCMS and Cromolyn+MCMS groups were exposed to injections of 0.2 ml autologous mast cell mediator suspension (1.5×10²/ml cells). Intact and compound 48/80-induced degranulated peritoneal mast cells are shown in Figures 1A and 1B.

**Figure 1A.** Intact peritoneal mast cells before compound 48/80 treatment in vitro. X40 magnification. Open arrowheads show intact mast cells (staining, toluidine blue).

**Figure 1B.** Degranulated peritoneal mast cells after compound 48/80 treatment in vitro. X40 magnification. Red solid arrowheads show degranulated mast cells (staining, toluidine blue).
2.5. Blood sample collection from animals

Two and a half hours after administration of drugs or autologous mast cell mediator suspension all rats were anesthetized with ketamine (90 mg/kg, i.p.). Blood was collected intracardially and coagulated at room temperature for 30 min. The blood samples were centrifuged at 3000 rpm, at 4 °C for 15 min. The supernatants were stored at –20 °C until assayed for substance-P immunoreactivity.

2.6. Dura mater preparations and toluidine blue staining for dural mast cells

After blood sample collection, all rats were instantly perfused intracardially with 100 ml phosphate-buffered saline (PBS; 0.1 M, pH 7.4) and PBS followed by 200 ml 4% paraformaldehyde. After perfusion process, whole-mount preparations of cranial dura mater were prepared on the glass slides as described previously (19). Briefly, the head was separated from the body, the skulls were opened carefully, and the dura maters were removed. The dura maters were postfixed in 4% paraformaldehyde solution overnight. Then, the dura maters were stained with toluidine blue staining (pH: 2.5) to observe mast cells in dura mater. Mast cells were counted in five objective areas including the main branches of the middle meningeal artery in both sides of dura mater, and categorized with regards to granulation or degranulation under a light microscope (Olympus CX21) by a blinded observer. The granulation term refers to the intact mast cells, on the contrary degranulation term expresses mast cells at the activated state that release various mediators such as histamine, prostaglandin, IL-1β from their cytoplasmic granules to outside the cell. The percent of degranulated mast cells in each dura mater was calculated as follows: [(number of degranulated mast cells)/ (number of total mast cells)] X 100%. Number of total mast cells and the percent of degranulated mast cells were calculated, and their microscopic images were taken with a camera (Nikon DS-Fi1, Nikon, Japan) which was attached to the microscope (Nikon Eclipse 80i, Nikon, Japan).

2.7. Measurement of substance-P levels in plasma

Substance-P content of plasma was measured using ELISA method with detection kits. The Substance-P detection limit is approximately 46.88 pg/ml. The protocol was carried out in reference to the manufacturer’s instructions and in duplicates. Briefly, 50 µL of substance-P standard or plasma samples were added to each well. Immediately after, 50 µL of biotinylated detection Ab was added to each well and the plates were incubated at 37 °C for 45 min. Followed by removal of liquid from each well 100 µL of HRP conjugate were added and the 96-well plates were incubated for 30 min at 37 °C. After the incubation, the wells were rinsed for 5 times with the wash buffer. Then 90 µL of substrate reagent was added to each well, finally, the plate was incubated for 15 min at 37 °C. After the incubation, 50 µL of stop solution was added to each well quickly. Then, optical density was measured at 450 nm using a microplate reader (Epoch BioTek Instruments, Inc. Highland Park, Winooski, VT, USA). Optical density curve was constituted by using standards with defined substance-P concentrations.

2.8. Statistical analysis

The data were stated as mean ± standard error of mean. Statistical analysis was performed using SPSS for Windows (version 17.0, SPSS Inc., Chicago, IL, USA). Statistical differences were determined using one-way analysis of variance test (ANOVA) followed by Dunnett’s post hoc test. p<0.05 was considered as statistically significant.

3. RESULTS

To activate mast cell degranulation, we used basic secretagogue agent compound 48/80, which leads to systemic mast cell degranulation through the body when administered intraperitoneally. Therefore intraperitoneal administration of compound 48/80 (2 mg/kg) induced massive degranulation of mast cells in the dura mater compared to controls (from 6.7±0.4% to 45.6±3.5%, p=0.0002, Figs. 2A, 2B and 3A).

Figure 2A. Normally intact mast cells in the dura mater in control group. X20 magnification. While open arrowheads show intact mast cells, red solid arrowheads show degranulated mast cells (staining, toluidine blue). MMA: middle meningeal artery.

Figure 2B. Compound 48/80-induced degranulation of mast cells in the dura mater in compound 48/80 treatment group. X20 magnification. While open arrowheads show intact mast cells, red solid arrowheads show degranulated mast cells (staining, toluidine blue). MMA: middle meningeal artery.
Mast cell Mediator Suspension in Inflammation

Figure 3A. While compound 48/80 and mast cell mediator suspension increased the percent of degranulated mast cells, these increments were inhibited by cromolyn, respectively. Mast cell mediator suspension further increased dural mast cell degranulation to compound 48/80. (**P<0.001, * versus control group; #P<0.05 and ###P<0.001, # versus compound 48/80 group; &P<0.05, & versus mast cell mediator suspension group). MC: mast cell, C-48/80: compound 48/80, MCMS: mast cell mediator suspension, Cr: cromolyn.

Moreover, intraperitoneal administration of compound 48/80 also increased plasma substance-P levels compared to controls (from 121.6±5.1 pg/ml to 154.5±4.3 pg/ml, p=0.01, Fig. 4), but it did not change total mast cell numbers in the dura mater compared to controls (from 358±20 to 360±10, p=0.87, Fig. 3B).

Figure 4. While compound 48/80 and mast cell mediator suspension increased the plasma substance-P levels, these increments were inhibited by cromolyn, respectively. Mast cell mediator suspension further increased the plasma substance-P levels to compound 48/80. (*P<0.05 and **P<0.001, * versus control group; #P<0.05, # versus compound 48/80 group; &P<0.05, & versus mast cell mediator suspension group). C-48/80: compound 48/80, MCMS: mast cell mediator suspension, Cr: cromolyn.

Figure 3B. While mast cell mediator suspension increased the number of mast cells in the dura mater, compound 48/80 did not change it. Cromolyn decreased the increments in the number of mast cells in the dura mater induced by mast cell mediator suspension. (**P<0.01, * versus control group; &P<0.05, & versus mast cell mediator suspension group).

To verify these effects of compound 48/80, we tested whether cromolyn sodium, a mast cell stabilizer, would prevent the actions induced by compound 48/80. When cromolyn was administered with compound 48/80 together, it blocked the effects of compound 48/80. Therefore cromolyn (10 mg/kg) prevented degranulation of mast cells in dura mater (45.6±3.5% in C-48/80 group versus 7.7±0.4% in Cromolyn+C-48/80 group, p=0.0003, Figs. 2C and 3A), and also it inhibited the increases in plasma substance-P levels induced by compound 48/80 (154.5±4.3 pg/ml in C-48/80 group versus 122.3±5.4 pg/ml in Cromolyn+C-48/80 group, p=0.007, Fig. 4).

Figure 2C. Inhibition of mast cell degranulation in the dura mater by cromolyn in cromolyn plus compound 48/80 group. X20 magnification. Open arrowheads show intact mast cells (staining, toluidine blue). MMA: middle meningeal artery.
On the other hand, to compare effects of compound 48/80 and autologous mast cell mediator suspension, we first isolated peritoneal mast cells (Fig. 1A) and degranulated them by treating compound 48/80 (10 µg/ml) in vitro (Fig. 1B). Then, autologous mast cell mediator suspension was administered to the rats, immediately. Autologous mast cell mediator suspension administration significantly increased both the percent of degranulated mast cells (from 6.7±0.4% to 67.7±4.9%, p=0.0001, Figs. 2D and Fig. 3A) and total mast cell numbers (from 358±20 to 501±10, p=0.002, Fig. 3B) in the dura mater. It also increased plasma substance-P levels (from 121.6±5.1 pg/ml to 203.1±11.1 pg/ml, p=0.0001, Fig. 4) compared to control. Interestingly, the triggering effect of mast cell mediator suspension administration on the degranulation of mast cells in the dura mater (45.6±3.5% in C-48/80 group versus 67.7±4.9% in MCMS group, p=0.047, Figs. 2B, 2D and 3A) and plasma substance-P levels (154.5±4.3 pg/ml in C-48/80 group versus 203.1±11.1 pg/ml in MCMS group, p=0.015, Fig. 4) was stronger than that of the compound 48/80. To clarify possible mechanism of these strong actions of mast cell mediator suspension, we tested whether cromolyn would inhibit the effects induced by mast cell mediator suspension. The results showed that cromolyn significantly attenuated both the percent of degranulated mast cells (67.7±4.9% in MCMS group versus 51.7±1.4% in Cromolyn+MCMS group, p=0.045, Figs. 2D, 2E, and 3A) and total mast cell numbers (501±10 in MCMS group versus 396±23 in Cromolyn+MCMS group, p=0.012, Fig. 3B) in the dura mater. It also reduced autologous mast cell mediator suspension administration induced plasma substance-P levels (203.1±11.1 pg/ml in MCMS group versus 158.5±3.5 pg/ml in Cromolyn+DM group, p=0.006, Fig. 4).

Figure 2D. Mast cell mediator suspension-induced massive degranulation of mast cells in the dura mater in peritoneal mast cell mediator suspension treatment group. X20 magnification. While open arrowheads show intact mast cells, red solid arrowheads show degranulated mast cells (staining, toluidine blue). MMA: middle meningeal artery.

Figure 2E. Inhibition of mast cell degranulation in the dura mater by cromolyn in cromolyn plus mast cell mediator suspension group. X20 magnification. While open arrowheads show intact mast cells, red solid arrowheads show degranulated mast cells (staining, toluidine blue). MMA: middle meningeal artery.

4. DISCUSSION

The mast cell degranulator compound 48/80 is a synthetic secretagogue agent and widely used for non-IgE dependent activation of mast cells. Compound 48/80 treatment stimulates inflammatory responses in a variety of animal models such as systemic anaphylaxis (20), central nervous system inflammation (21), dural neurogenic inflammation and activation of trigeminal neurons in migraine (22), mast cell-mediated hyperalgesia (23), allergic inflammation and neuropathic pain (24). But in these models, compound 48/80 treatment leads to systemic mast cell degranulation throughout all body. Such applications make it difficult to focus on a specific disease in animal models of acute and chronic inflammation. The local application of compound 48/80 can solve the problem at the least in the tissues containing mast cells. In relation to this, we have recently shown that topical application of compound 48/80 to meninges evoked potently nociceptive firing in meningeal trigeminal nerve fibers in ex-vivo rat meningeal preparations through mast cell degranulation (22). But it is hard to see a specific or local effect of compound 48/80 treatment during in vivo applications because compound 48/80 diffuses almost all tissues of the body when it is injected. Therefore, in the present study, we used MC mediator suspension obtained from peritoneal mast cells degranulated by compound 48/80 for the first time to develop a model with both local and systemic effect for inflammatory diseases.

MC mediator suspension treatment exhibited more powerful effects than the effect of compound 48/80 on the plasma SP levels and number as well as degranulation of mast cells in the dura mater which are the most important markers of inflammation and acute inflammatory pain. In the present study, we chose plasma SP levels, and number
and degranulation states of mast cells in the dura mater to
evaluate inflammation and inflammatory pain because of
these parameters are accepted as valuable markers in most
inflammatory diseases (3,7, 12, 25, 26).

It is known that mast cells and SP contribute a plethora
of proinflammatory effects (12, 25). It was reported that
SP levels and NK-1R expression were increased in the
rectum and colon of patients with inflammatory bowel
disease and in the synovial fluid and serum of patients with
rheumatoid arthritis (27, 28). Moreover, SP leads to release
of inflammatory mediators such as cytokines, serotonin,
histamine, TNF-α, oxygen radicals and arachidonic acid
derivatives from mast cells through receptor-independent
mechanism. In a clinical study, a positive correlation
has been shown between the plasma levels of SP and
intensity of chronic pain in patients with osteoarthritis and
rheumatoid arthritis (12). In the present study, we showed
that intraperitoneal administration of compound 48/80
raised the plasma levels of SP, which is a critical marker of
inflammation and inflammatory pain. However, mast cell
stabilizers are also very important agents to control the
plasma levels of SP in certain inflammatory diseases. It was
reported that pretreatment with the mast cell stabilizer
cromolyn decreased plasma levels of SP, CGRP and trypase
in transgenic sickle mice (29). Likewise, in the current
study, pretreatment with the mast cell stabilizer cromolyn
significantly diminished plasma levels of SP induced by
compound 48/80 or mast cell mediator suspension.
Inhibition of mast cell activation can be a considerable tool
to prevent subsequent chronic inflammatory conditions
such as asthma, headache, allergic and rheumatic disorders.
For example, some mast cell stabilizers including ketotifen
and cromolyn have been successfully used in the treatment
of various allergic disorders (9). Moreover, reduction of mast
cell numbers and/or inhibition of mast cell degranulation
in their resident environment are also very important in the
treatment of inflammatory diseases.

In the current study, cromolyn inhibited mast cell
degranulation in the dura mater evoked by compound 48/80
or mast cell mediator suspension. Moreover, cromolyn
decreased also mast cell mediator suspension-induced
increments in the number of mast cells in the dura mater.
Our findings are in accordance with the literature reporting
the effects of the number and degranulation of mast cells
in the inflammatory diseases (6, 7, 26). Previously published
studies in the literature reported that there is an increase in
the number and degranulation of mast cells in inflammatory
pain conditions (6, 7, 26). The cranial dura mater is densely
innervated by trigeminal afferent nerve fibers, and contains
numerous mast cells.

Chemical or mechanical irritation of the dura mater causes
release of vasoactive and proinflammatory neuropeptides
such as SP and CGRP from trigeminal nerve terminals
innervating the dura mater (4, 30, 31). Released SP and
CGRP leads to plasma protein extravasation, vasodilatation
of meningeal blood vessels and dural mast cell degranulation
which constitute triple trivet of dural neurogenic inflammation
underlying migraine pain (5). Moreover degranulated mast
cells in the dura mater release vasoactive, nociceptive and
proinflammatory mediators such as SP, CGRP, serotonin,
prostaglandins, histamine and a plethora of cytokines
(2) which, in turn, further strengthen dural neurogenic
inflammation and pain. On this basis, researchers developed
an animal model of migraine through applying an inflammatory
cocktail to dura mater to induce local inflammation at the
dura mater (32, 33). This inflammatory cocktail known as
inflammatory soup comprises an combination of serotonin,
bradykinin, histamine, and prostaglandin PGE2. Mast
cells are known to contain these mediators. Such animal
models to study inflammatory pain and hyperalgesia cannot
mimic all characteristics of inflammatory pains due to the
presence of only mast cell derived limited mediators such as
serotonin, bradykinin, histamine, and prostaglandin PGE2.
Therefore, in the current study, we suggest a more realistic
model including application of MC derived mediators to
study mechanisms, pathophysiology and treatment of local
or systemic inflammatory diseases. Moreover this new
method has a number of advantages compared to existing
methods. These are i) mast cell mediator suspension
contain all mediators in the cytoplasmic granules of mast
cells, ii) mediators used in the study are not synthetic, iii)
the mediator suspension is autologous, iv) the mediator
suspension also contains cytokines that are responsible
for a broad spectrum of inflammatory responses, v) the
mediator suspension can be applied intraperitoneally to
induce systemic inflammatory conditions, or topically to
constitute site-specific inflammatory diseases, vi) it can
also be injected to cutaneous tissues, joints and muscles to
establish local inflammatory diseases, vii) mast cell stabilizer
cromolyn can be used as positive control to compare efficacy
of new therapeutic agents for the treatment of inflammatory
diseases.

5. CONCLUSION

Our results showed that administration of mast cell mediator
suspension exhibited more potent inflammatory effects than
compound 48/80 treatment, in terms of the increments in
the plasma SP levels and the number and degranulation of
dural MCs. Therefore intraperitoneal administration of mast
cell mediator suspension could be a useful tool to investigate
mechanisms of inflammatory conditions that are particularly
associated with the degranulation of MCs.

However, our study has several limitations. These limitations
are i) other inflammatory markers including, IL-1β, bradykinin,
TNF-α in peripheral blood should be studied following
autologous mast cell mediator suspension administration, ii)
in addition to pain and inflammatory markers in the plasma,
behavioral tests such as von Frey and hot plate as indicator
for the pain should also be performed to evaluate mast cell
mediator suspension-induced inflammatory pain, iii) dose
adjustment of autologous mast cell mediator suspension
administration should be studied in rats, mice and rabbits, and iv) further studies supporting our results are required.

**Conflict of Interest:** All authors declare no conflict of interest.

**Financial Disclosure:** No financial support by any institution. Authors financially supported this study.

**REFERENCES**


